Cell-based therapies, enzyme inhibitors at vanguard of muscular dystrophy treatment

ORLANDO, Fla. — Cell-based therapies and enzyme inhibitors currently in development are likely to become the next-generation treatments for ambulatory and non-ambulatory forms of muscular dystrophy, according to a speaker.
“The approved therapies in Duchenne are corticosteroid agents,” Dimah Saade, MD, clinical assistant professor in the division of neurology in the Stead Family department of pediatrics at the University of Iowa’s Carver College of Medicine, said during her presentation at the American Neurological Association annual meeting. “There are treatment

ORLANDO, Fla. — Cell-based therapies and enzyme inhibitors currently in development are likely to become the next-generation treatments for ambulatory and non-ambulatory forms of muscular dystrophy, according to a speaker.
“The approved therapies in Duchenne are corticosteroid agents,” Dimah Saade, MD, clinical assistant professor in the division of neurology in the Stead Family department of pediatrics at the University of Iowa’s Carver College of Medicine, said during her presentation at the American Neurological Association annual meeting. “There are treatment